An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

NCT03060577 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

382

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerotic Cardiovascular Disease
Symptomatic Atherosclerosis
Type2 Diabetes
Familial Hypercholesterolemia

Interventions

DRUG: Inclisiran
DRUG: Evolocumab

Sponsor

Novartis Pharmaceuticals